Antiviral drug discovery: preparing for the next pandemic

Catherine S Adamson; Kelly Chibale; Rebecca Goss; Marcel Jaspars; David J. Newman; Rosemary A. Dorrington

doi:10.1039/D0CS01118E

Antiviral drug discovery: preparing for the next pandemic

Catherine S Adamson, Kelly Chibale, Rebecca Goss, Marcel Jaspars, David J. Newman, Rosemary A. Dorrington

Research output: Contribution to journal › Review article › peer-review

145 Citations (Scopus)

13 Downloads (Pure)

Abstract

Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine development is underway. We review the current status of antiviral therapies focusing on RNA viruses, highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to accelerate drug discovery efforts.

Original language	English
Number of pages	9
Journal	Chemical Society Reviews
Volume	Advance Article
Early online date	1 Feb 2021
DOIs	https://doi.org/10.1039/D0CS01118E
Publication status	E-pub ahead of print - 1 Feb 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1039/D0CS01118ELicence: CC BY-NC

Adamson-2021-Antiviral-drug-discovery-ChemSocRev-CC
Copyright © 2021 the Author(s). Open Access Article. This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.
Final published version, 2.25 MBLicence: CC BY-NC

Suppressing SARS-CoV-2: Suppressing SARS-CoV-2 transmission in public spaces through surface
Smith, T. K. (PI) & Adamson, C. S. (CoI)
Medical Research Council
1/09/20 → 31/08/21
Project: Standard

Cite this

@article{1f1f7490589446a7aa1bb2e833ed555f,

title = "Antiviral drug discovery: preparing for the next pandemic",

abstract = "Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine development is underway. We review the current status of antiviral therapies focusing on RNA viruses, highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to accelerate drug discovery efforts.",

author = "Adamson, {Catherine S} and Kelly Chibale and Rebecca Goss and Marcel Jaspars and Newman, {David J.} and Dorrington, {Rosemary A.}",

note = "Funding: South African Medical Research Council (MRC) with funds received from the South African National Department of Health and the UK Government{\textquoteright}s Newton Fund (R.A.D., RL.M.G., K.C.), the UK Engineering and Physical Sciences Research Council EQATA (R.J.M.G.), the UK Global Challenge Research Fund (R.J.M.G., R.A.D.), the University of Cape Town (K.C.) and the South African Research Chairs Initiative of the Department of Science and Innovation, administered through the South African National Research Foundation (K.C. R.A.D.). C.S.A. acknowledges financial support for SARS-CoV-2/Covid-19 research from UKMRC (CVG-1725-2020) and UKRI-DHSC (MR/V028464/1).",

year = "2021",

month = feb,

day = "1",

doi = "10.1039/D0CS01118E",

language = "English",

volume = "Advance Article",

journal = "Chemical Society Reviews",

issn = "0306-0012",

publisher = "Royal Society of Chemistry",

}

TY - JOUR

T1 - Antiviral drug discovery

T2 - preparing for the next pandemic

AU - Adamson, Catherine S

AU - Chibale, Kelly

AU - Goss, Rebecca

AU - Jaspars, Marcel

AU - Newman, David J.

AU - Dorrington, Rosemary A.

N1 - Funding: South African Medical Research Council (MRC) with funds received from the South African National Department of Health and the UK Government’s Newton Fund (R.A.D., RL.M.G., K.C.), the UK Engineering and Physical Sciences Research Council EQATA (R.J.M.G.), the UK Global Challenge Research Fund (R.J.M.G., R.A.D.), the University of Cape Town (K.C.) and the South African Research Chairs Initiative of the Department of Science and Innovation, administered through the South African National Research Foundation (K.C. R.A.D.). C.S.A. acknowledges financial support for SARS-CoV-2/Covid-19 research from UKMRC (CVG-1725-2020) and UKRI-DHSC (MR/V028464/1).

PY - 2021/2/1

Y1 - 2021/2/1

N2 - Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine development is underway. We review the current status of antiviral therapies focusing on RNA viruses, highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to accelerate drug discovery efforts.

AB - Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine development is underway. We review the current status of antiviral therapies focusing on RNA viruses, highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to accelerate drug discovery efforts.

U2 - 10.1039/D0CS01118E

DO - 10.1039/D0CS01118E

M3 - Review article

SN - 0306-0012

VL - Advance Article

JO - Chemical Society Reviews

JF - Chemical Society Reviews

ER -

Antiviral drug discovery: preparing for the next pandemic

Abstract

UN SDGs

Access to Document

Fingerprint

Projects

Suppressing SARS-CoV-2: Suppressing SARS-CoV-2 transmission in public spaces through surface

Cite this